Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Published byKrista Adenauer Modified over 5 years ago

Similar presentations

Presentation on theme: "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study "— Presentation transcript:

1 Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study  Andrew Blauvelt, MD, MBA, Kristian Reich, MD, Tsen-Fang Tsai, MD, Stephen Tyring, MD, PhD, Francisco Vanaclocha, MD, Külli Kingo, MD, PhD, Michael Ziv, MD, BSc, Andreas Pinter, MD, Ronald Vender, MD, FRCPC, Sophie Hugot, MSc, Ruquan You, MSc, Marina Milutinovic, MD, Diamant Thaçi, MD  Journal of the American Academy of Dermatology  Volume 76, Issue 1, Pages e9 (January 2017) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Study design to week 52. ↓ = Active dose administration; to keep the study blinded, subjects in the ustekinumab treatment group received placebo secukinumab injections. *Ustekinumab dose was based on body weight per label: 45 mg for subjects ≤100 kg and 90 mg for subjects >100 kg. BL, Baseline; PASI 75/90, ≥75%/≥90% improvement from baseline Psoriasis Area and Severity Index score. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 PASI 90 (A), PASI 100 (B), PASI 75 (C), and IGA 0/1 (D) responses until week 52. Missing data were handled using multiple imputation. *P < .05, †P < .01, and ‡P < .001 vs ustekinumab by logistic regression. IGA mod /1, Investigator's Global Assessment, 2011 modified version, score 0/1; PASI 75/90/100, ≥75%/≥90%/100% improvement from baseline Psoriasis Area and Severity Index score. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Proportions of subjects with a DLQI score 0 or 1 over time. Missing data were imputed with last observation carried forward. *P < .05 and †P < .001 vs ustekinumab by the Fisher's exact test. DLQI, Dermatology Life Quality Index. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 A, Percentages of subjects with impairment* in EQ-5D-3L domains at baseline and week 52. B, Percentage reductions in impairment on the WPAI-PSO from baseline to week 52. Missing data were imputed with the last observation carried forward. *Subjects rated their level of impairment in each dimension with 1 of 3 categories of response (no problem, moderate problem, or severe problems); this figure shows the percentages of subjects who reported moderate or severe problems in each dimension. †P < .01 vs ustekinumab by analysis of covariance. EQ-5D, EuroQoL 5-Dimension Health Questionnaire (EQ-5D; version EQ-5D-3L); WPAI-PSO, Work Productivity and Activity Impairment Questionnaire-Psoriasis. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Percentages of subjects with concomitant PsA exhibiting HAQ-DI response* over time. Missing data were imputed with the last observation carried forward. *HAQ-DI response was defined as a decrease in score of at least 0.3 from baseline, the minimum clinically important difference (score range: 0-3). HAQ-DI, Health Assessment Questionnaire-Disability Index. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

7 Supplemental Fig 1 Subject disposition. *Four subjects did not receive study treatment (2 withdrew consent: 1 due to a technical problem and 1 due to physician decision) and discontinued the study at randomization; 1 was excluded from all analyses because the informed consent form was obtained the day after a study-related procedure. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

8 Supplemental Fig 2 PASI 90 response rates at week 16 and week 52: secukinumab vs. ustekinumab 45 mg or 90 mg. Missing data were handled by using nonresponder imputation. PASI 90, ≥90% improvement from baseline Psoriasis Area and Severity Index score. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

9 Supplemental Fig 3 PASI 90 response rates at week 16 (A) and week 52 (B) by previous psoriasis therapy exposure. Missing data were handled by using multiple imputation. P values by logistic regression. PASI 90, ≥90% improvement from baseline Psoriasis Area and Severity Index score. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

10 Supplemental Fig 4 PASI 90 responses to week 52 in the subgroup with concomitant psoriatic arthritis at baseline. Missing data were handled by using nonresponder imputation. *P < .05, †P < .01, and ‡P < .001 vs ustekinumab by logistic regression. PASI 90, ≥90% improvement from baseline Psoriasis Area and Severity Index score. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

11 Supplemental Fig 5 Subject's assessment of psoriasis-related pain (A), itching (B), and scaling (C) over time. Missing data were handled by using last observation carried forward. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

12 Supplemental Fig 6 Mean percentage improvements from baseline in DLQI total score and individual subscales at week 52. Missing data were imputed with last observation carried forward. *P = .0002 vs ustekinumab by the van Elteren test. P values for subscales were not assessed. DLQI, Dermatology Life Quality Index. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study "

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States  Caroline P. Schaefer,

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States  Caroline P. Schaefer,
Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Similar presentations

Ads by Google